University of Rochester
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.
Inclusion Criteria: 1. Participants must be \>18 years old at time of diagnosis 2. Histologically confirmed non-small cell lung cancer 3. ECOG PS 2 4. Clinical staging of IIIc or IV disease. 4A. For patients with stage IIIc disease, patients are ineligible for or refuse standard treatment with platinum-double chemotherapy and radiation. 4B. For patients with stage IV disease, platinum doublet chemotherapy is not appropriate, deemed unsafe by the treating physician, or declined by the patient 4C. Screening lab work must meet the following parameters: 4Ca. Absolute neutrophil count (ANC) ≥1…
Pembrolizumab 200 mg
500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
Arctuva estimate
Verify or correct the compensation shown for this listing.